Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$1.07
+4.9%
$1.18
$0.82
$4.08
$273.62M0.264.47 million shs22.92 million shs
NextCure, Inc. stock logo
NXTC
NextCure
$2.02
-8.2%
$7.85
$1.78
$15.74
$7.95M1.3158,655 shs59,376 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.42
+0.7%
$1.26
$0.98
$1.60
$1.06B1.52.71 million shs5.23 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+4.90%+18.97%+19.54%-24.65%-69.94%
NextCure, Inc. stock logo
NXTC
NextCure
-8.18%-9.42%-77.88%-79.78%-62.81%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+0.71%-2.07%+23.48%+26.79%+10.08%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$1.07
+4.9%
$1.18
$0.82
$4.08
$273.62M0.264.47 million shs22.92 million shs
NextCure, Inc. stock logo
NXTC
NextCure
$2.02
-8.2%
$7.85
$1.78
$15.74
$7.95M1.3158,655 shs59,376 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.42
+0.7%
$1.26
$0.98
$1.60
$1.06B1.52.71 million shs5.23 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+4.90%+18.97%+19.54%-24.65%-69.94%
NextCure, Inc. stock logo
NXTC
NextCure
-8.18%-9.42%-77.88%-79.78%-62.81%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+0.71%-2.07%+23.48%+26.79%+10.08%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
2.20
Hold$4.67336.14% Upside
NextCure, Inc. stock logo
NXTC
NextCure
2.40
Hold$23.001,038.61% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.559.15% Upside

Current Analyst Ratings Breakdown

Latest OPK, AKBA, and NXTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2026
NextCure, Inc. stock logo
NXTC
NextCure
UpgradeStrong SellHold
5/18/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
UpgradeSell (E+)Sell (D-)
5/6/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Reiterated RatingSell (E+)
5/6/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
DowngradeHoldStrong Sell
5/6/2026
NextCure, Inc. stock logo
NXTC
NextCure
DowngradeHoldStrong Sell
5/4/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeSell (D-)Sell (E+)
4/29/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeOutperformMarket Perform
4/27/2026
NextCure, Inc. stock logo
NXTC
NextCure
Reiterated RatingSell (D-)
4/21/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Reiterated RatingSell (D-)
4/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
UpgradeStrong SellHold
4/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Reiterated RatingBuy$4.00
(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$236.20M1.22N/AN/A$0.12 per share8.92
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/A$9.97 per shareN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.77N/AN/A$1.67 per share0.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)
NextCure, Inc. stock logo
NXTC
NextCure
-$55.84M-$17.19N/AN/AN/AN/A-186.96%-124.62%8/6/2026 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)

Latest OPK, AKBA, and NXTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 million
5/7/2026Q1 2026
NextCure, Inc. stock logo
NXTC
NextCure
-$2.1050-$1.87+$0.2350-$1.87N/AN/A
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1.33
1.40
1.33
NextCure, Inc. stock logo
NXTC
NextCure
N/A
4.61
4.61
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
NextCure, Inc. stock logo
NXTC
NextCure
42.65%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.30%
NextCure, Inc. stock logo
NXTC
NextCure
11.90%
OPKO Health, Inc. stock logo
OPK
OPKO Health
44.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430268.26 million256.72 millionOptionable
NextCure, Inc. stock logo
NXTC
NextCure
903.61 million3.18 millionNo Data
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million417.42 millionOptionable

Recent News About These Companies

Spotlight On Promising Penny Stocks For May 2026

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$1.07 +0.05 (+4.90%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$1.06 -0.01 (-0.47%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

NextCure stock logo

NextCure NASDAQ:NXTC

$2.02 -0.18 (-8.18%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$2.12 +0.10 (+4.90%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.42 +0.01 (+0.71%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$1.44 +0.02 (+1.41%)
As of 06/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.